Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 6/20 | 0.34 |
| ▸ | CTSS | P25774 | 6/20 | 0.34 |
| ▸ | CTSK | P43235 | 6/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345223 | 0.85 | CTSB (0.36) | SMN1; SMN2CTSBCTSSCTSKCYP1A2 | |
| SCHEMBL23995711 | 0.81 | CYP1A2 (0.38) | SMN1; SMN2CTSBCTSSCTSKCYP1A2 | |
| SCHEMBL24597150 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP1A2TDP1CYP2D6 | |
| SCHEMBL25450310 | 0.72 | CCR6 (0.31) | — | |
| SCHEMBL23075986 | 0.70 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP1A2TDP1 | |
| SCHEMBL25093254 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2TDP1 | |
| SCHEMBL23344765 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP1A2TDP1 | |
| SCHEMBL23075806 | 0.68 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2TDP1CYP2D6 | |
| SCHEMBL23344769 | 0.68 | CYP2D6 (0.31) | CYP2D6 | |
| SCHEMBL21997890 | 0.66 | HSD11B1 (0.35) | CTSBCTSSCTSKCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | SMN1; SMN2 375/4885CTSB 2814/4885CTSS 2095/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | SMN1; SMN2 432/4885CTSB 1337/4885CTSS 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.